Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing-Remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05438693
What this trial is testing

Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
doaa mokhtar mahmoud 80
Large-scale testing (Phase 3)Study completedNCT01442233
What this trial is testing

Plasma Exchanges in Multiple Sclerosis (MS) Relapses

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Acute Relapsing
University Hospital, Bordeaux 38
Not applicableStudy completedNCT04832399
What this trial is testing

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 60
Not applicableUnknownNCT04236544
What this trial is testing

Patient Experiences of Multiple Sclerosis (PExMS)

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingPatient Engagement+1 more
Universitätsklinikum Hamburg-Eppendorf 55
Not applicableStudy completedNCT00493298
What this trial is testing

Tysabri Observational Program

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 6,620
Large-scale testing (Phase 3)Study completedNCT02861014
What this trial is testing

Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Hoffmann-La Roche 681
Testing effectiveness (Phase 2)Study completedNCT02040298
What this trial is testing

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University of California, San Francisco 50
Testing effectiveness (Phase 2)Study completedNCT00349193
What this trial is testing

Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 306
Not applicableLooking for participantsNCT06586177
What this trial is testing

Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Heinrich-Heine University, Duesseldorf 100
Early research (Phase 1)Study completedNCT01466322
What this trial is testing

Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GlaxoSmithKline 16
Not applicableStudy completedNCT05351411
What this trial is testing

Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Firat University 60
Large-scale testing (Phase 3)Ended earlyNCT04032171
What this trial is testing

Study of Evobrutinib in Participants With RMS

Who this might be right for
Relapsing-remitting Multiple Sclerosis
EMD Serono Research & Development Institute, Inc. 1
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07222956
What this trial is testing

Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remittingMultiple Sclerosis (MS) Secondary ProgressiveMultiple Sclerosis (MS) Primary Progressive
Moein Amin 20
Post-approval studies (Phase 4)Study completedNCT02471560
What this trial is testing

Tecfidera and the Gut Microbiota

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 36
Post-approval studies (Phase 4)WithdrawnNCT02675413
What this trial is testing

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Washington University School of Medicine
Not applicableStudy completedNCT02490982
What this trial is testing

Teriflunomide Observational Effectiveness Study

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Centre hospitalier de l'Université de Montréal (CHUM) 106
Large-scale testing (Phase 3)Study completedNCT04115488
What this trial is testing

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)
Polpharma Biologics S.A. 265
Not applicableUnknownNCT05705986
What this trial is testing

Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)

Who this might be right for
Relapse Remitting Multiple Sclerosis
Thomas Jefferson University 40
Not applicableStudy completedNCT00461396
What this trial is testing

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Bayer 104
Large-scale testing (Phase 3)Study completedNCT00451451
What this trial is testing

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 1,417
Next Page